Pyramid Analytics and Smollan forge international partnership
22.8.2023 16:06:00 EEST | Business Wire | Press release
Global retail specialists Smollan have formalised an international reseller and implementation partnership agreement with next-generation decision and business intelligence (BI) software provider Pyramid Analytics. The agreement will see Smollan, via its data and technology business, DataOrbis, expanding its current service offering to include the ability to both sell Pyramid Analytics licenses and implement Pyramid Analytics software.
“Our clients operate in incredibly competitive industries, where the ability to make the best decision, quickly is the key to strong performance. Our hunt for a BI solution that delivers superior functionality, excellent value, and next-generation capability led us to Pyramid Analytics. We migrated the majority of our DataOrbis solutions onto their software last year, and already our clients are noticing a step-change in how we can help them capitalise on the explosive amount of data they have at their fingertips,” said James Collett, Smollan’s Chief Executive: Data & Technology.
The Pyramid Analytics partnership also provides DataOrbis with a growth opportunity geared at expanding DataOrbis’ services and footprint into verticals outside of the fast-moving consumer goods (FMCG) space where they have traditionally played. This is further supported by DataOrbis and Smollan’s global footprint, which includes operations in all major gateways.
“DataOrbis has an excellent understanding of what it takes to implement a successful data strategy across an organisation, regardless of industry. We are incredibly excited to be partnering with them internationally. By leveraging their global presence throughout their client and partner networks, I believe DataOrbis, together with Pyramid Analytics, can streamline and optimise their data analytics ecosystems to prepare them for what’s next. We are thrilled to have them on board,” said Omri Kohl, Pyramid Analytics CEO.
The Pyramid Platform consistently receives top ratings among leading analyst firms that evaluate business intelligence and analytics technologies. Most recently, Pyramid earned top rankings from Gartner in the 2023 Critical Capabilities for Analytics and Business Intelligence Platforms report, including #1 for Business Analyst Use Case, #1 for Augmented Consumer Use Case, #2 for Data Scientist Use Case, and #4 for Analytics Developer Use Case.
The Pyramid Platform consolidates data preparation, business analytics, and data science into a single, integrated, self-service platform that can be accessed by all levels of data users.
“The time it takes for a decision-maker to access data can make or break a company’s competitive advantage. Pyramid Analytics reduces the amount of time it takes users across the organisation to easily find the information they need without having to request it from IT. It’s a win-win for both users and overly stretched IT departments,” said Kohl.
Implementation is key to success
As the need to unlock the power of data has accelerated, businesses are realising the benefit of having one enterprise BI platform across the organisation, ensuring a single source of truth that can be safely, securely, and ethically managed. As an early adopter, DataOrbis has invested in creating and upskilling several Pyramid Analytics’ implementation teams working out of South Africa, India, and Slovenia to assist clients in creating and implementing their own unique global views. These teams, with over 50 certified Pyramid Analytics specialists, include senior resources with expertise across industries and geographies.
“The choice of BI platform is one part of the insights puzzle. The skill and time needed to implement the software is the next piece. In our experience, most companies don’t have these two vital resources readily available. By partnering with DataOrbis we can ensure the Pyramid Analytics software is expertly implemented and used to its fullest potential—all based on global best-practises. I am excited by the opportunities the Pyramid Analytics partnership will unlock for us and our clients,” said Collett.
ABOUT
Pyramid Analytics
Pyramid Analytics is the next generation of business analytics. The award-winning Pyramid Decision Intelligence Platform empowers people with augmented, automated, and collaborative insights that simplify and guide the use of data in decision-making. Critically, the Pyramid Analytics Platform operates directly on any data, enabling governed self-service for any person, and meeting analytical needs in a no-code environment without data extraction. It combines data prep, business analytics, and data science into one frictionless platform to empower anyone with intelligent decision-making. This enables a strategic, enterprise-wide approach to business intelligence and analytics, from the simple to the sophisticated. Schedule a demo. To find out more about Pyramid Analytics contact pr@pyramidanalytics.com.
Smollan
Founded in 1931, Smollan is a global commerce business, delivering growth for retailers and brand owners across five continents. Influencing what, when, where and shoppers browse and buy across multiple touchpoints, through Sales & Merchandising, Activation & Experience, Data & Technology and Digital Commerce. Internationally recognised for our exceptional human platform of over 75 000 people and our sophisticated systems, we drive sales and create brilliant shopper experiences for some of the world’s most loved brands. We are a global business that helps retailers and brands win at the point of purchase. Contact us at www.smollan.com.
DataOrbis
A leading data and technology company, DataOrbis uses its SMART ecosystem of services, solutions and technology to expertly help companies transform into businesses driven by data. With over 50 blue-chip clients, DataOrbis currently processes over 300 sources of data across 60+ countries in multiple languages. In 2020, DataOrbis joined forces with global retail specialist Smollan, increasing its ability to scale, expand and network globally.
DataOrbis is headquartered in South Africa with offices and partners across the globe. To find out more about DataOrbis contact us here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230822485425/en/
Contact information
Pete Vomocil
Senior Vice President, Global Marketing, Pyramid Analytics
E-Mail: pr@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom